Business
Sernova Announces American Transplant Congress 2021 Virtual Connect Abstract Presentation
(TheNewswire) L ondon, Ontario - TheNewswire - June 1, 2021 -...
About this update from Sernova Biotherapeutics Inc
[{"type":"text","content":"Sernova Announces American Transplant Congress 2021 Virtual Connect Abstract Presentation\n \n \n (TheNewswire)\n \n \n \n \n \n \n \n \n L\n \n \n ondon, Ontario\n \n \n -\n \n \n TheNewswire -\n \n \n June 1, 2021 -\nSernova Corp. (TSXV:SVA) (OTC:SEOVF\n \n \n )\n \n \n (FSE/XETRA:PSH\n \n ), a leading clinical-stage regenerative\nmedicine therapeutics company, is pleased to announce that lead\nprincipal investigator Dr. Piotr Witkowski and the Clinical Trial\nInvestigator Team for its US Phase I/II Type 1 Diabetes clinical trial\nwill present data and observations from the ongoing study in a\npresentation at the upcoming American Transplant Congress (ATC)\nVirtual Connect to be held June 4 - 9, 2021.\n \n \n The live presentation entitled “\n \n Islet Allotransplantation Into the Pre-Vascularized Sernova Cell\nPouch\n \n \n TM\n \n \n Device - Preliminary Results\nfrom University of Chicago\n \n ” will be available to conference\nattendees on Saturday, June 5, 2021 at 6:30pm ET.\n \n \n \n ABOUT SERNOVA’S CELL POUCH\nSYSTEM\n \n \n \n The Cell Pouch, as part of the Cell Pouch System, is a novel,\nproprietary, scalable, implantable macro- encapsulation device\nsolution designed for the long-term survival and function of\ntherapeutic cells. The device upon implantation is designed to\nincorporate with tissue, forming highly vascularized tissue chambers\nfor the transplantation and function of therapeutic cells, which then\nrelease proteins and hormones as required to treat disease. The Cell\nPouch, along with therapeutic cells, has been shown to provide\nlong-term safety and efficacy in small and large animal models of\ndiabetes and has been proven to provide a biologically compatible\nenvironment for insulin-producing cells in humans.\n \n \n \n ABOUT SERNOVA\n \n \n \n Sernova is developing regenerative medicine therapeutic technologies\nusing a medical device and immune protected therapeutic cells (i.e.\nhuman donor cells, corrected human cells and stem cell-derived cells)\nto improve the treatment and quality of life of people with chronic\nmetabolic diseases such as insulin-dependent diabetes, blood disorders\nincluding hemophilia, and other diseases treated through replacement\nof proteins or hormones missing or in short supply within the body.\nFor more information, please visit\n \n www.sernova.com\...